Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Immunovant ( (IMVT) ) is now available.
On December 10, 2025, Immunovant, Inc. entered into an underwriting agreement with Leerink Partners LLC for the issuance and sale of 26.2 million shares of its common stock at $21.00 per share. The offering, which closed on December 12, 2025, raised approximately $550 million in gross proceeds, enhancing the company’s financial position and potentially impacting its market strategy.
The most recent analyst rating on (IMVT) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Immunovant stock, see the IMVT Stock Forecast page.
Spark’s Take on IMVT Stock
According to Spark, TipRanks’ AI Analyst, IMVT is a Neutral.
Immunovant’s stock score is primarily impacted by substantial financial weaknesses, including ongoing losses and cash flow issues. Technical indicators are bearish, further weighing on the stock’s attractiveness. However, recent positive clinical trial results and leadership changes provide some optimism, potentially strengthening the company’s pipeline and long-term prospects.
To see Spark’s full report on IMVT stock, click here.
More about Immunovant
Immunovant, Inc. operates in the biopharmaceutical industry, focusing on developing treatments for autoimmune diseases.
Average Trading Volume: 1,736,624
Technical Sentiment Signal: Buy
Current Market Cap: $4.13B
Find detailed analytics on IMVT stock on TipRanks’ Stock Analysis page.